InsiderTrades

Form 4 for JBIO Jade Biosciences, Inc.

Accepted 2024-03-11 00:00:00 ET · period of report 2024-03-07 · accession 0001415889-24-007533 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-03-11 2024-03-07 JBIO Gillies Hunter Chief MEDICAL Off S - Sale+OE $24.50 -8,975 3,251 -73% -$219.9K
D 2024-03-11 2024-03-07 JBIO Gillies Hunter Chief MEDICAL Off M - OptEx $2.14 +8,975 12.2K +276% +$19.2K
DM 2024-03-11 2024-03-07 JBIO Gillies Hunter Chief MEDICAL Off M - OptEx $0.00 -8,975 101.5K -8% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-03-07 S D 8,975 $24.50 3,251 D — —
2 Common Common Stock 2024-03-07 M A 8,975 $2.14 12,226 D — —
3 Derivative Stock Option (Right to Buy) 2024-03-07 M D 945 $0.00 15,324 D $2.14 · — to 2031-04-01 945 Common Stock (F2) A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.
4 Derivative Stock Option (Right to Buy) 2024-03-07 M D 8,030 $0.00 101,510 D $2.14 · — to 2031-04-01 8,030 Common Stock (F3) A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments.